The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy

Editorial summary Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Genome medicine Ročník 11; číslo 1; s. 43 - 3
Hlavní autoři: Sabio, Erich, Chan, Timothy A.
Médium: Journal Article
Jazyk:angličtina
Vydáno: London BioMed Central 24.07.2019
BioMed Central Ltd
BMC
Témata:
ISSN:1756-994X, 1756-994X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Editorial summary Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In this perspective, we synthesize and summarize some important issues surrounding hyperprogression, defining characteristics, prognostic implications, and controversies.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1756-994X
1756-994X
DOI:10.1186/s13073-019-0661-7